Publications

Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case of Olaratumab

Pontes Caridad, Zara Corinne, Torrent-Farnell Josep, Obach Merce, Nadal Cristina, Vella-Bonanno Patricia, Ermisch Michael, Simoens Steven, Curi Hauegen Renata, Gulbinovic Jolanta, Timoney Angela, Martin Antony P, Mueller Tanja, Nachtnebel Anna, Campbell Stephen, Selke Gisbert, Bochenek Tomasz, Rothe Celia C, Mardare Ileana, Bennie Marion, Fürst Jurij, Malmstrom Rickard E, Godman Brian

Applied Health Economics and Health Policy Vol 18, pp. 5-16 (2020)

https://doi.org/10.1007/s40258-019-00527-x

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Godman Brian, Malmström Rickard E, Diogene Eduardo, Gray Andy, Jayathissa Sisira, Timoney Angela, Acurcio Francisco, Alkan Ali, Brzezinska Anna, Bucsics Anna, Campbell Stephen M, Czeczot Jadwiga, de Bruyn Winnie, Eriksson Irene, Yusof Faridah Aryani Md, Finlayson Alexander E, Fürst Jurij, Garuoliene Kristina, Guerra Júnior Augusto, Gulbinovič Jolanta, Jan Saira, Joppi Roberta, Kalaba Marija, Magnisson Einar, McCullagh Laura, Miikkulainen Kaisa, Ofierska-Sujkowska Gabriela, Pedersen Hanne Bak, Selke Gisbert, Sermet Catherine, Spillane Susan, Supian Azuwana, Truter Ilse, Vlahović-Palčevski Vera, Vien Low Ee, Vural Elif H, Wale Janet, Władysiuk Magdałene, Zeng Wenjie, Gustafsson Lars L

Expert Review of Clinical Pharmacology Vol 8, pp. 77-94 (2015)

https://doi.org/10.1586/17512433.2015.990380

More publications